Is this page useful for you? Then, help us to keep the service working. Please have a look to our donations page ... Thanks for your help!!

Citation Profile [Updated: 2024-11-03 20:16:59]
5 Years H Index
Impact Factor (IF)
0
5 Years IF
0
Data available in this report

[Raw data] [50 most cited papers] [50 most relevant papers] [cites used to compute IF] [Recent citations ][Frequent citing series ] [more data in EconPapers] [trace new citations] [Missing citations? Add them now] [Incorrect content? Let us know]

Main indicators
Raw Data

 

IF AIF CIF IF5 DOC CDO CIT NCI CCU D2Y C2Y D5Y C5Y SC %SC CiY II AII
IF: Two years Impact Factor: C2Y / D2Y
AIF: Average Impact Factor for all series in RePEc in year y
CIF: Cumulative impact factor
IF5: Five years Impact Factor: C5Y / D5Y
DOC: Number of documents published in year y
CDO: Cumulative number of documents published until year y
CIT: Number of citations to papers published in year y
NCI: Number of citations in year y
CCU: Cumulative number of citations to papers published until year y
D2Y: Number of articles published in y-1 plus y-2
C2Y: Cites in y to articles published in y-1 plus y-2
D5Y: Number of articles published in y-1 until y-5
C5Y: Cites in y to articles published in y-1 until y-5
SC: selft citations in y to articles published in y-1 plus y-2
%SC: Percentage of selft citations in y to articles published in y-1 plus y-2
CiY: Cites in year y to documents published in year y
II: Immediacy Index: CiY / Documents.
AII: Average Immediacy Index for series in RePEc in year y
50 most cited documents in this series
#YearTitleCited
1Integer/Linear Mathematical Programming Models: A Tool for Allocating Healthcare Resources. (2003). Earnshaw, Stephanie R. ; Dennett, Susan L.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:12:p:839-851.

Full description at Econpapers || Download paper

18
2Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies. (2008). Godman, Brian ; Schwabe, Ulrich ; Garattini, Silvio ; Joppi, Roberta . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:2:p:91-98.

Full description at Econpapers || Download paper

5
3Cost of Schizophrenia to UK Society: An Incidence-Based Cost-of-Illness Model for the First 5 Years Following Diagnosis. (1999). Guest, Julian F. ; Cookson, Ron F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:15:y:1999:i:6:p:597-610.

Full description at Econpapers || Download paper

3
4QALYs: Are They Helpful to Decision Makers?. (2006). Caro, Jaime J. ; McGregor, Maurice . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:10:p:947-952.

Full description at Econpapers || Download paper

3
5Modelling in Health Economic Evaluation: What is its Place? What is its Value?. (2000). Akehurst, Ron . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:5:p:445-459.

Full description at Econpapers || Download paper

2
6European Healthcare Policies for Controlling Drug Expenditure. (2003). Schneeweiss, Sebastian ; Szucs, Thomas D. ; Ess, Silvia M.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:2:p:89-103.

Full description at Econpapers || Download paper

2
7NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective. (2008). Lewis, Gavin ; Earnshaw, Julia . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:9:p:725-727.

Full description at Econpapers || Download paper

2
8Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). (2001). Harris, Anthony ; Mitchell, Andrew ; George, Bethan . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109.

Full description at Econpapers || Download paper

2
9The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?. (2008). Jommi, Claudio . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:5-15.

Full description at Econpapers || Download paper

2
10The Economic Impact of Parkinson`s Disease: An Estimation Based on a 3-Month Prospective Analysis. (1998). Rathay, Bernard ; Oertel, Wolfgang H. ; Szucs, Thomas ; Kohne-Volland, Rudolf ; Dodel, Richard C. ; Singer, Marikka ; Scholz, Erich . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:3:p:299-312.

Full description at Econpapers || Download paper

1
11The Cost of Treatment of Alzheimers Disease in The Netherlands: A Regression-Based Simulation Model. (2001). Ruitenberg, Annemieke ; van der Roer, Nicole ; Monique M. B. Breteler, ; Redekop, Ken W. ; McDonnell, Joseph ; Jan J. V. Busschbach, ; Frans F. H. Rutten, ; Goes, Elles . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:4:p:379-390.

Full description at Econpapers || Download paper

1
12Incorporating Carer Effects into Economic Evaluation. (2006). Walker, Mel ; Dixon, Simon ; Salek, Sam . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:1:p:43-53.

Full description at Econpapers || Download paper

1
13Annual Cost of Erectile Dysfunction to UK Society. (1999). Plumb, Jonathan M. ; Guest, Julian F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:16:y:1999:i:6:p:699-709.

Full description at Econpapers || Download paper

1
14The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4. (2008). Mitchell, Andrew ; Scuffham, Paul A. ; Whitty, Jennifer A.. In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:4:p:297-310.

Full description at Econpapers || Download paper

1
15Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers. (2006). Gafni, Amiram ; Birch, Stephen . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:11:p:1121-1131.

Full description at Econpapers || Download paper

1
16Prospective Study Designs in Outcomes Research: The Case of Migraine. (2002). Gomez-Mancilla, Baltazar ; Schonfeld, Warren H. ; Brod, Meryl I. ; Rothermich, Elizabeth A. ; Rowland, Clayton R.. In: PharmacoEconomics. RePEc:wkh:phecon:v:20:y:2002:i:11:p:715-725.

Full description at Econpapers || Download paper

1
17Cost of Illness in Adult Patients with Hypopituitarism. (2000). Bengtsson, Bengt-Ake ; Rosen, Thord ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Ehrnborg, Christer ; Jonsson, Bjorn . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:621-628.

Full description at Econpapers || Download paper

1
18Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review. (2010). Puig-Junoy, Jaume . In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:8:p:649-663.

Full description at Econpapers || Download paper

1
19The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency. (1998). Stevenaert, Achille ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Beckers, Albert . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:395-403.

Full description at Econpapers || Download paper

1
20An Economic Overview of Chronic Obstructive Pulmonary Disease. (2001). Dasbach, Erik J. ; Ruchlin, Hirsch S.. In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:623-642.

Full description at Econpapers || Download paper

1
21Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. (2008). Cruess, Alan F. ; Xu, Xiao ; Knight, Tyler ; Goss, Thomas F. ; Buggage, Ronald ; Mones, Jordi ; Soubrane, Gisele ; Zlateva, Gergana ; Pauleikhoff, Daniel ; Schaefer, Caroline ; Lotery, Andrew . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:57-73.

Full description at Econpapers || Download paper

1
22Expert Judgement in Pharmacoeconomic Studies: Guidance and Future Use. (2000). Crawford, Bruce ; Evans, Christopher . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:545-553.

Full description at Econpapers || Download paper

1
23The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. (2003). Nordmann, Alain J. ; Krahn, Murray ; Naglie, Gary ; Detsky, Allan S. ; Logan, Alexander G.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:8:p:573-585.

Full description at Econpapers || Download paper

1
24Cant Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products. (2010). Towse, Adrian ; Garrison, Louis P.. In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:2:p:93-102.

Full description at Econpapers || Download paper

1
25Does Managed Care Fuel Pharmaceutical Industry Growth?. (1998). Deardorff, Frank W. ; Murray, Michael D.. In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:341-348.

Full description at Econpapers || Download paper

1
26Developing Guidance for Budget Impact Analysis. (2001). Hutton, John ; Trueman, Paul ; Drummond, Michael . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:609-621.

Full description at Econpapers || Download paper

1
50 most relevant documents in this series (papers most cited in the last two years)
#YearTitleCited
Citing documents used to compute impact factor:
YearTitle
Recent citations
10 most frequent citing series
#SeriesHCites